AXSOME THERAPEUTICS INC's ticker is AXSM and the CUSIP is 05464T104. A total of 2 filers reported holding AXSOME THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $519,283 | -2.9% | 7,430 | -0.2% | 0.01% | 0.0% |
| Q2 2023 | $534,998 | +15.3% | 7,445 | -1.0% | 0.01% | +20.0% |
| Q1 2023 | $463,834 | -39.4% | 7,520 | -24.3% | 0.01% | -44.4% |
| Q4 2022 | $765,901 | +59.2% | 9,930 | -7.9% | 0.01% | +50.0% |
| Q3 2022 | $481,000 | -17.2% | 10,780 | -29.0% | 0.01% | -14.3% |
| Q2 2022 | $581,000 | -6.4% | 15,180 | +1.1% | 0.01% | 0.0% |
| Q1 2022 | $621,000 | +14.6% | 15,010 | +4.7% | 0.01% | +16.7% |
| Q4 2021 | $542,000 | +0.7% | 14,335 | -12.2% | 0.01% | 0.0% |
| Q3 2021 | $538,000 | -14.6% | 16,325 | +74.9% | 0.01% | -14.3% |
| Q2 2021 | $630,000 | +24.0% | 9,335 | +4.0% | 0.01% | +16.7% |
| Q1 2021 | $508,000 | -13.5% | 8,980 | +24.6% | 0.01% | -33.3% |
| Q4 2020 | $587,000 | +17.6% | 7,205 | +2.9% | 0.01% | 0.0% |
| Q3 2020 | $499,000 | +55.9% | 7,000 | +79.7% | 0.01% | +50.0% |
| Q2 2020 | $320,000 | -12.8% | 3,895 | +9.7% | 0.01% | 0.0% |
| Q4 2019 | $367,000 | – | 3,550 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ALETHEA CAPITAL MANAGEMENT, LLC | 1,132,645 | $37,332,000 | 32.86% |
| MORGAN JESS S & CO INC | 113,430 | $3,739,000 | 2.47% |
| Fairmount Funds Management LLC | 187,598 | $6,183,000 | 2.25% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 1,423,653 | $46,924,000 | 1.43% |
| WMS Partners, LLC | 250,000 | $8,240,000 | 1.21% |
| Beck Bode, LLC | 102,127 | $3,366,000 | 0.94% |
| RTW INVESTMENTS, LP | 1,616,497 | $53,280,000 | 0.80% |
| MPM BioImpact LLC | 110,155 | $3,631,000 | 0.56% |
| Endurant Capital Management LP | 52,048 | $1,716,000 | 0.39% |
| Bellevue Group AG | 752,945 | $24,817,000 | 0.25% |